Skip to main content
. Author manuscript; available in PMC: 2010 Nov 15.
Published in final edited form as: Cancer Res. 2010 May 11;70(10):3985–3995. doi: 10.1158/0008-5472.CAN-09-3604

Figure 5. AML1/ETO proteins inhibit Brn3a function in myeloid differentiation.

Figure 5

A, B) FACS analysis of CD11b and CD117 expression at day 3 on progenitors infected at day 0 with pMSCV-GFP (GFP) or pMiG-AML1/ETO (AML1/ETO) or pMiG-AML1/ETO9a (AML1/ETO9a) and at day 1 with either pMSCV-hCD2 (hCD2 control) or pMSCV-3a-hCD2 (Brn3a). Graph represents mean percentage of total viable population ± S.D. from three experiments. Differentiated cell number (c-Kit−/CD11b+) relative to progenitor number (c-Kit+/CD11b−) was increased in Brn3a/GFP cultures (P=0.013), not significantly different in Brn3a/AML1ETO cultures (P=0.386), and decreased in Brn3a/AML1ETO9a cultures (P=0.010). C) Morphology of FACS-sorted GFP+/hCD2+ cells. D) Real-time PCR analysis of gene expression relative to that of 18s in hCD2+/GFP+ sorted progenitors 48 hr after dual-transduction, relative to hCD2/GFP control.